

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEVADA**

SPECTRUM PHARMACEUTICALS, INC.  
and UNIVERSITY OF STRATHCLYDE,

Case No.: 2:12-cv-00111-GMN-NJK

## Yankees,

## **CORRECTED ORDER**

SANDOZ INC..

## Defendant.

This Order *corrects* a clerical error in the original Order filed on December 31, 2013 at No. 199, as follows: on page 8, FN1, diastereoisomer is corrected to read diastereoisomer. Other aspects of the original Order remain the same.

Pending before the Court are the proposed claim constructions submitted by Plaintiffs Spectrum Pharmaceuticals, Inc. and University of Strathclyde (collectively, “Plaintiffs”) and Defendant Sandoz Inc. (“Defendant”). Plaintiff filed its Opening Brief on August 27, 2012 (ECF No. 49), Defendant filed a Responsive Brief on September 10, 2012 (ECF No. 53), and Plaintiff filed a Reply Brief on September 17, 2012 (ECF No. 56). Subsequently, the Court permitted the parties to file supplemental claim construction briefing. (ECF No. 66.) Thereafter, Defendant filed its supplemental briefing on November 26, 2012 (ECF No. 75) and Plaintiffs filed their supplemental brief on December 3, 2012 (ECF No. 81). The Court held a Tutorial Hearing on December 5, 2012, and a *Markman* Claim Construction Hearing on December 11, 2012.

This is an Order construing the disputed terms of the claims in United States Patent No. 6,500,829 (“the ’829 Patent”). The parties have submitted nine terms, phrases or groups thereof for construction. (*See generally* Pls.’ Br. 6–30, ECF No. 49; Def.’s Resp. 5–27, ECF No. 53.) In


1 addition, the parties agree on the construction of one additional term. (See Resp. 27 n.15.) The  
 2 Court will adopt the proposed claim construction for the one term on which the parties agree, as  
 3 reflected herein.

4 After consideration of the briefs and material submitted by the parties, the arguments of  
 5 counsel at the claim construction hearing, and the record before the Court, the Court issues this  
 6 Order construing the disputed claim terms.

7 **I. BACKGROUND**

8 5-formyl-(6R,S)-tetrahydrofolic acid is the chemical name for a compound more  
 9 commonly known as leucovorin. This compound has been used since the 1950s to prevent the  
 10 toxic side-effects of methotrexate, a commonly used chemotherapy agent. U.S. Patent No.  
 11 6,500,829 col.1 ll.22–24 (filed Apr. 18, 1995). Essentially, leucovorin protects the patient’s  
 12 healthy cells while still allowing the methotrexate to kill the cancerous cells. *Id.* at col.1 ll.24–  
 13 29. Without leucovorin, methotrexate would also kill many of the patient’s healthy cells. *Id.*  
 14 This use of leucovorin is known as “methotrexate rescue.” *Id.* at col.1 ll.24–29.

15 As the name suggests, 5-formyl-(6R,S)-tetrahydrofolic acid contains an asymmetric, or  
 16 chiral, center at the 6 carbon. *Id.* at col.1 ll.34–35.



23 This chiral center causes leucovorin to exist as a 50-50 mixture of two diastereoisomers denoted  
 24 as the “6R” isomer and the “6S” isomer. *Id.* However, only the 6S isomer, known as  
 25 “levoleucovorin,” is the effective methotrexate rescue agent. *Id.* at col.1 ll.57–61. For this

1 reason, scientists began attempting to separate the 6S isomer from the 6R isomer to enable  
 2 administration of a higher dosage of the effective 6S isomer. Although other scientists have  
 3 previously discovered methods of synthesis or isolation, these methods either produced low  
 4 yields or failed to achieve reasonable purity. *See id.* at col.2 ll.13–23.

5 In response to the shortcomings of the prior art methods of separating and purifying  
 6 levoleucovorin, a team of researchers from Plaintiff University of Strathclyde filed a patent  
 7 application, which eventually issued as the '829 Patent. Specifically, the '829 Patent discloses  
 8 "substantially pure" levoleucovorin compositions, which have "most preferably greater than  
 9 95%" of the (6S) isomer. *Id.* at col.4 ll.26–29. The '829 Patent describes that substantially pure  
 10 6R and 6S samples can be achieved in good yield by introducing a "chiral auxiliary group into  
 11 tetrahydrofolate or a tetrahydrofolate derivative" close to the chiral center at the 6 carbon. *Id.*  
 12 col.2, ll.24–29. The '829 Patent further discloses that "[t]he pair of new diastereoisomers so  
 13 created [could] be separated by standard techniques such as crystallisation, chromatography,  
 14 solvent extraction and similar methods." *Id.* col.3 ll.42–45. The chosen method of purification  
 15 can be repeated to improve purity. *Id.* col.3 ll.54–56. "Conveniently the step may be repeated  
 16 until the recovered new diastereoisomer has a purity greater than 90%." *Id.* col.3 ll.56–58.

17 After filing a New Drug Application ("NDA") with the FDA, Plaintiff Spectrum  
 18 Pharmaceuticals, Inc. received approval to market this substantially pure form of levoleucovorin  
 19 under the trade name "Fusilev®." The FDA approved Fusilev® "to treat patients diagnosed  
 20 with advanced metastatic colorectal cancer . . . to effect 'methotrexate rescue.'" (Pls.' Claim  
 21 Construction Br. 4:2–4, ECF No. 49.)

22 In 2011, Defendant Sandoz filed an Abbreviated New Drug Application ("ANDA") with  
 23 the FDA, pursuant to 21 U.S.C. § 355(j), seeking to market a proposed generic version of  
 24 Fusilev®. As required by section 355(j)(2)(A)(vii), Defendant certified in its ANDA that the  
 25 manufacture, use, or sale of its generic version of Fusilev® would not infringe any valid,

1 enforceable claim of any patent that covers Fusilev®. In addition, as required by  
 2 section 355(j)(2)(B)(iii), Defendant provided notice of its ANDA to the owner of the '829  
 3 Patent, Plaintiff University of Strathclyde, 21 U.S.C. § 355(j)(2)(B)(iii)(I), and to the holder of  
 4 the approved NDA that is covered by the '829 Patent, Plaintiff Spectrum Pharmaceuticals, 21  
 5 U.S.C. § 355(j)(2)(B)(iii)(II).

6 In response, Plaintiffs filed the instant action alleging infringement of the '829 Patent.  
 7 (Compl. ¶¶ 21–28, ECF No. 1.) Specifically, Plaintiffs assert that Defendant's proposed generic  
 8 levoleucovorin product infringes claims 1, 2, and 5–14 of the '829 Patent. (Pls.' Claim  
 9 Construction Br. 4:14.)

10 **II. LEGAL STANDARD**

11 The resolution of patent infringement actions generally requires two distinct steps. First,  
 12 the Court engages in a claim construction analysis to “determin[e] the meaning and scope of the  
 13 patent claims asserted to be infringed.” *Markman v. Westview Instruments, Inc.*, 52 F.3d 967,  
 14 976 (Fed. Cir. 1995) (en banc), aff'd 517 U.S. 370 (1996). Only once the claims are properly  
 15 construed does the action proceed to the second step, in which the factfinder compares those  
 16 properly construed claims to the accused device to determine, as a matter of fact, whether all of  
 17 the claim limitations are present in the accused device. *Id.* At the current stage of this patent  
 18 infringement action, the Court focuses only on the first step.

19 **A. Claim Construction**

20 “It is a bedrock principle of patent law that the claims of a patent define the invention to  
 21 which the patentee is entitled the right to exclude.” *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312  
 22 (Fed.Cir.2005) (en banc) (citations and internal quotation marks omitted). The interpretation of  
 23 the scope and meaning of disputed terms in patent claims is a question of law and exclusively  
 24 within the province of a court to decide. *Markman*, 517 U.S. at 372. When construing disputed  
 25 claim terms, the Court must give each disputed term “the meaning that the term would have to a

1 person of ordinary skill in the art at the time of the invention,” unless the patentee clearly  
2 intended a different definition. *Phillips*, 415 F.3d at 1312–13. Furthermore, “the person of  
3 ordinary skill in the art is deemed to read the claim term not only in the context of the particular  
4 claim in which the disputed term appears but in the context of the entire patent, including the  
5 specification.” *Id.* at 1313.

6 In certain cases, “the ordinary meaning of claim language as understood by a person of  
7 skill in the art may be readily apparent even to lay judges, and claim construction in such cases  
8 involves little more than the application of the widely accepted meaning of commonly  
9 understood words.” *Id.* at 1314. In other instances, the claim term may have a particular  
10 meaning in the field of art that is not immediately clear. *Id.* In such cases, the Federal Circuit  
11 has instructed that a court’s analysis should focus on the intrinsic evidence, including “the words  
12 of the claims themselves, the remainder of the specification, the prosecution history, and  
13 extrinsic evidence concerning relevant scientific principles, the meaning of technical terms, and  
14 the state of the art.” *Id.* at 1314. “[T]he claims themselves provide substantial guidance as to the  
15 meaning of particular claim terms.” *Id.* “Other claims of the patent in question, both asserted  
16 and unasserted, can also be valuable sources of enlightenment as to the meaning of a claim  
17 term.” *Id.* Specifically, differences between the claims often provide useful guidance in  
18 understanding the meaning of the claim terms. *Id.* “For example, the presence of a dependent  
19 claim that adds a particular limitation gives rise to a presumption that the limitation in question  
20 is not present in the independent claim.” *Id.* at 1314–15.

21 The claims, however, are not read in isolation, but are read in light of the entire  
22 specification, of which the claims are a part. *Id.* In fact, the specification is “the single best  
23 guide to the meaning of a disputed term.” *Vitronics Corp. v. Conceptronic, Inc.*, 90 F.3d 1576,  
24 1582 (Fed. Cir. 1996). Courts can also look to the prosecution history as part of the intrinsic  
25 record to determine how the Patent Office and the inventor understood the patent. *Phillips*, 415

1 F.3d at 1317. However, the prosecution history lacks the clarity of the specification and more  
 2 often is less useful for claim construction purposes. *Id.*

3 Finally, extrinsic evidence may also be relevant to claim construction. *Id.* Extrinsic  
 4 evidence “consists of all evidence external to the patent and prosecution history, including  
 5 expert and inventor testimony, dictionaries, and learned treatises.” *Markman*, 52 F.3d at 980.  
 6 Although such evidence may aid the Court in construing claim terms, “it is unlikely to result in a  
 7 reliable interpretation of patent claim scope unless considered in the context of the intrinsic  
 8 evidence.” *Phillips*, 415 F.3d at 1319. Thus, “while extrinsic evidence can shed useful light on  
 9 the relevant art, . . . it is less significant than the intrinsic record in determining the legally  
 10 operative meaning of claim language.” *Id.* at 1317 (internal quotation marks omitted).

11 **III. THE LEVEL OF ORDINARY SKILL**

12 Patent claims are to be construed to reflect the understanding of an ordinary worker in the  
 13 appropriate field. *Phillips*, 415 F.3d at 1312–13 (“[T]he ordinary and customary meaning of a  
 14 claim term is the meaning that the term would have to a person of ordinary skill in the art in  
 15 question at the time of the invention . . .”). Thus, in the claim construction process, the Court  
 16 first determines the level of ordinary skill in the relevant technology. In making this  
 17 determination, the Court considers the complexity of the technology, the pace of technological  
 18 advancement in the field, and the education and experience of those working in the area. *See*  
 19 *Daiichi Sankyo Co., Ltd. v. Apotex, Inc.*, 501 F.3d 1254, 1257 (Fed. Cir. 2007).

20 In this case, both parties agree that the appropriate level of skill is “a Ph.D. in organic  
 21 chemistry with some industrial, or post-doctoral experience.” (Jones Decl. ¶ 8, ECF No. 55; *see*  
 22 *also* Pls.’ Br. 8, n.31, ECF No. 49 (stating that, in the context of the ’829 Patent, “one of  
 23 ordinary skill in the art” would typically be a “Ph.D. chemist[] with some industrial  
 24 experience”)).

25 // /

1      **IV. CONSTRUCTION OF THOSE TERMS ON WHICH THE PARTIES AGREE**

2      In Defendant's Responsive Claim Construction Brief, Defendant stated its agreement  
 3      with Plaintiffs' proposed construction of "said composition is produced as a result of separation  
 4      by differential solubility" (Def.'s Resp. Claim Construction Br. 27 n.15, ECF No. 53 ("Upon  
 5      review of Plaintiffs' brief and their statements regarding the claim term 'said composition is  
 6      provided as a result of separation by differential solubility . . . , ' Sandoz now agrees with  
 7      Plaintiffs' proposed construction of that term.").) The Court hereby adopts this proposed  
 8      construction. Therefore, the Court construes the term "said composition is produced as a result  
 9      of separation by differential solubility" as "the pharmaceutically acceptable composition is  
 10     produced as a result of separation by differential solubility in a polar solvent of a (6S)  
 11     diastereoisomer from an initial mixture containing equal amounts of (6S) and (6R)  
 12     diastereoisomers." (Pls.' Br. 29:11–18.)

13      **V. CONSTRUCTION OF THE DISPUTED CLAIM TERMS**

14      In their respective claim construction briefs, the parties identified nine categories of claim  
 15     terms that are in need of the Court's construction: (1) "mixture"; (2) the "percentage" claim  
 16     terms; (3) "the balance of said compound consisting of the (6R) diastereoisomers";  
 17     (4) "pharmaceutical composition for therapeutic use (for the treatment of human beings)";  
 18     (5) "pharmaceutical composition for preparing medicaments for therapeutic use in the treatment  
 19     of human beings"; (6) the "pharmaceutically acceptable" claim terms; (7) "consists essentially  
 20     of"; (8) the "multiple dose" claim terms; and (9) claim 13's reference to claim 11 and claim 14's  
 21     reference to claim 10. The disputed claim terms are emphasized below.

22      Claim 1:

23      A **pharmaceutical composition for therapeutic use** which **consists essentially**  
 24      **of** a therapeutically effective amount sufficient for the treatment of human beings  
 25      for methotrexate rescue or folate deficiency, of a **pharmaceutically acceptable**  
**compound** which is a (6S) diastereoisomers selected from the group consisting of  
 (6S) leucovorin (5-formyl-( 6S)-tetrahydrofolic acid) and pharmaceutically

1 acceptable salts and esters of (6S) leucovorin; wherein the compound consists of a  
 2 **mixture** of (6S) and (6R) diastereoisomers and consists of **at least 92% by**  
**weight of the (6S) diastereoisomer, the balance of said compound consisting of**  
**the (6R) diastereoisomer;** in combination with a pharmaceutically acceptable  
 3 carrier.

4 Claim 5:

5 A **pharmaceutical composition for therapeutic use for the treatment of**  
 6 **human beings** comprising:

7 a **pharmaceutically acceptable composition** which is a (6S) diastereoisomer  
 8 selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-  
 9 tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S)  
 10 leucovorin, wherein the composition consists of a **mixture** of (6S) and (6R)  
 11 diastereoisomers and consists of **at least about 92% by weight** of the (6S)  
 12 diastereoisomer, **the balance of said composition consisting of the (6R)**  
**diastereoisomer;** and  
 13 a pharmaceutically acceptable carrier; and  
 14 said composition being of a quantity at least sufficient to provide multiple doses  
 15 of said **mixture** of (6S) and (6R) diastereoisomers **in an amount of 2000 mg**  
**per dose.**

16 Claim 10:

17 A **pharmaceutical composition for preparing medicaments for therapeutic**  
 18 **use in the treatment of human beings** consisting of a **mixture** of:

19 a (6S) diastereois[o]mer<sup>1</sup> selected from the group consisting of (6S) leucovorin  
 20 (5-formyl-( 6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts  
 21 and esters of (6S) leucovorin and the (6R) diastereoisomer thereof;  
 22 wherein said **mixture** of (6S) and (6R) diastereoisomers consists of **at least**  
**about 92% by weight** of the (6S) diastereoisomer, **the balance of said**  
**composition consisting of the (6R) diastereoisomer;** and  
 23 said **mixture** of (6S) and (6R) diastereoisomers being present in said  
 24 pharmaceutical composition in an aggregate quantity at least sufficient to  
 25 provide multiple doses of said **mixture in an amount of 2000 mg per dose.**

26 Finally, the parties dispute whether claims 13 and 14 are drafted in dependent or  
 27 independent form and also dispute the validity of these two claims.

28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871  
 872  
 873  
 874  
 875  
 876  
 877  
 878  
 879  
 880  
 881  
 882  
 883  
 884  
 885  
 886  
 887  
 888  
 889  
 890  
 891  
 892  
 893  
 894  
 895  
 896  
 897  
 898  
 899  
 900  
 901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948  
 949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979  
 980  
 981  
 982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998  
 999  
 1000  
 1001  
 1002  
 1003  
 1004  
 1005  
 1006  
 1007  
 1008  
 1009  
 1010  
 1011  
 1012  
 1013  
 1014  
 1015  
 1016  
 1017  
 1018  
 1019  
 1020  
 1021  
 1022  
 1023  
 1024  
 1025  
 1026  
 1027  
 1028  
 1029  
 1030  
 1031  
 1032  
 1033  
 1034  
 1035  
 1036  
 1037  
 1038  
 1039  
 1040  
 1041  
 1042  
 1043  
 1044  
 1045  
 1046  
 1047  
 1048  
 1049  
 1050  
 1051  
 1052  
 1053  
 1054  
 1055  
 1056  
 1057  
 1058  
 1059  
 1060  
 1061  
 1062  
 1063  
 1064  
 1065  
 1066  
 1067  
 1068  
 1069  
 1070  
 1071  
 1072  
 1073  
 1074  
 1075  
 1076  
 1077  
 1078  
 1079  
 1080  
 1081  
 1082  
 1083  
 1084  
 1085  
 1086  
 1087  
 1088  
 1089  
 1090  
 1091  
 1092  
 1093  
 1094  
 1095  
 1096  
 1097  
 1098  
 1099  
 1100  
 1101  
 1102  
 1103  
 1104  
 1105  
 1106  
 1107  
 1108  
 1109  
 1110  
 1111  
 1112  
 1113  
 1114  
 1115  
 1116  
 1117  
 1118  
 1119  
 1120  
 1121  
 1122  
 1123  
 1124  
 1125  
 1126  
 1127  
 1128  
 1129  
 1130  
 1131  
 1132  
 1133  
 1134  
 1135  
 1136  
 1137  
 1138  
 1139  
 1140  
 1141  
 1142  
 1143  
 1144  
 1145  
 1146  
 1147  
 1148  
 1149  
 1150  
 1151  
 1152  
 1153  
 1154  
 1155  
 1156  
 1157  
 1158  
 1159  
 1160  
 1161  
 1162  
 1163  
 1164  
 1165  
 1166  
 1167  
 1168  
 1169  
 1170  
 1171  
 1172  
 1173  
 1174  
 1175  
 1176  
 1177  
 1178  
 1179  
 1180  
 1181  
 1182  
 1183  
 1184  
 1185  
 1186  
 1187  
 1188  
 1189  
 1190  
 1191  
 1192  
 1193  
 1194  
 1195  
 1196  
 1197  
 1198  
 1199  
 1200  
 1201  
 1202  
 1203  
 1204  
 1205  
 1206  
 1207  
 1208  
 1209  
 1210  
 1211  
 1212  
 1213  
 1214  
 1215  
 1216  
 1217  
 1218  
 1219  
 1220  
 1221  
 1222  
 1223  
 1224  
 1225  
 1226  
 1227  
 1228  
 1229  
 1230  
 1231  
 1232  
 1233  
 1234  
 1235  
 1236  
 1237  
 1238  
 1239  
 1240  
 1241  
 1242  
 1243  
 1244  
 1245  
 1246  
 1247  
 1248  
 1249  
 1250  
 1251  
 1252  
 1253  
 1254  
 1255  
 1256  
 1257  
 1258  
 1259  
 1260  
 1261  
 1262  
 1263  
 1264  
 1265  
 1266  
 1267  
 1268  
 1269  
 1270  
 1271  
 1272  
 1273  
 1274  
 1275  
 1276  
 1277  
 1278  
 1279  
 1280  
 1281  
 1282  
 1283  
 1284  
 1285  
 1286  
 1287  
 1288  
 1289  
 1290  
 1291  
 1292  
 1293  
 1294  
 1295  
 1296  
 1297  
 1298  
 1299  
 1300  
 1301  
 1302  
 1303  
 1304  
 1305  
 1306  
 1307  
 1308  
 1309  
 1310  
 1311  
 1312  
 1313  
 1314  
 1315  
 1316  
 1317  
 1318  
 1319  
 1320  
 1321  
 1322  
 1323  
 1324  
 1325  
 1326  
 1327  
 1328  
 1329  
 1330  
 1331  
 1332  
 1333  
 1334  
 1335  
 1336  
 1337  
 1338  
 1339  
 1340  
 1341  
 1342  
 1343  
 1344  
 1345  
 1346  
 1347  
 1348  
 1349  
 1350  
 1351  
 1352  
 1353  
 1354  
 1355  
 1356  
 1357  
 1358  
 1359  
 1360  
 1361  
 1362  
 1363  
 1364  
 1365  
 1366  
 1367  
 1368  
 1369  
 1370  
 1371  
 1372  
 1373  
 1374  
 1375  
 1376  
 1377  
 1378  
 1379  
 1380  
 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398  
 1399  
 1400  
 1401  
 1402  
 1403  
 1404  
 1405  
 1406  
 1407  
 1408  
 1409  
 1410  
 1411  
 1412  
 1413  
 1414  
 1415  
 1416  
 1417  
 1418  
 1419  
 1420  
 1421  
 1422  
 1423

## A. “Mixture”

## Proposed Constructions<sup>2</sup>

<b>Spectrum</b>	Plain Meaning: “a mixture of (6S) and (6R) diastereoisomers of leucovorin”
<b>Sandoz</b>	“a two-component combination consisting of non-negligible amounts of each of the (6S) and (6R) diastereoisomers, and excludes pure (6S) diastereoisomers”

The term “mixture” appears in Claims 1, 5-7, and 10-12.

## **1. Plaintiffs' Proposed Construction**

Plaintiffs contend that the term “mixture” needs no further construction. (See Pls.’ Br. 11:17–12:8, ECF No. 49.) Essentially, Plaintiffs argue that the term “mixture” is clear on its face and, as a result, no further understanding or explanation is needed.

“The construction of claims is simply a way of elaborating the normally terse claim language in order to understand and explain, but not to change, the scope of the claims.” *Terlep v. Brinkmann Corp.*, 418 F.3d 1379, 1382 (Fed. Cir. 2005) (citations omitted). Furthermore, when the claim language is “clear on its face,” then the Court’s “consideration of the rest of the intrinsic evidence is restricted to determining if a deviation from the clear language of the claims is specified.” *Interactive Gift Exp., Inc. v. Compuserve Inc.*, 256 F.3d 1323, 1331 (Fed. Cir. 2001).

Here, the term “mixture” needs no further construction; this is not the type of “terse claim language” that needs further elaboration before the jury will understand the meaning of the phrase. The Court finds that one of skill in the art would need no further explanation, other than the words of the claim, to determine the identity of the components in the claimed “mixture.” For the same reason, the Court concludes that one of skill in the art would understand that a “mixture” requires the presence of both of the components listed in the claim language. There is

<sup>2</sup> Throughout this Order, Plaintiffs' proposed constructions are taken from their Opening Claim Construction Brief. (See ECF No. 49.) Similarly, throughout this Order, Defendant's proposed constructions are taken from its Responsive Claim Construction Brief. (See ECF No. 53.)

1 no evidence in the words of the '829 Patent that indicate that the term "mixture" is used in  
 2 anything other than its ordinary meaning. *See O2 Micro Int'l Ltd. v. Beyond Innovation Tech.*  
 3 *Co., Ltd.*, 521 F.3d 1351, 1361 (Fed. Cir. 2008) ("A determination that a claim term 'needs no  
 4 construction' or has the 'plain and ordinary meaning' may be inadequate when a term has more  
 5 than one 'ordinary' meaning or when reliance on a term's 'ordinary' meaning does not resolve  
 6 the parties' dispute").

7 **2. *Defendant's Proposed Construction.***

8 Defendant requests that this Court construe the term "mixture" as "a two-component  
 9 combination consisting of non-negligible amounts of each of the (6S) and (6R)  
 10 diastereoisomers, and excludes pure (6S) diastereoisomers." For the reasons discussed below,  
 11 the Court disagrees that such construction is correct.

12 a. "non-negligible"

13 Defendant first argues that its construction is correct because, without the "non-  
 14 negligible" language, the "(6R) diastereoisomers" and "mixture" limitations would be rendered  
 15 meaningless. (Resp. 5:18–21, ECF No. 53.) However, the Court is not persuaded that  
 16 Defendant's proposed construction must be adopted to limit the '829 Patent to "substantially  
 17 pure" diastereoisomers rather than "pure" diastereoisomers.

18 First, the claim language itself expressly recites a composition that contains *both* isomers.  
 19 '829 Patent col.9, ll.62–64. Furthermore, the specification states that the '829 Patent relates to  
 20 the preparation of "substantially pure diastereoisomers." Accordingly, the Court agrees with  
 21 Defendant that one of skill in the art would not read the '829 Patent as claiming "pure" (6S)  
 22 diastereoisomers. Nevertheless, the Court is not persuaded that this alone requires that the  
 23 construction of "mixture" include the term "non-negligible." In fact, the Court is concerned that  
 24 incorporating "non-negligible" would create additional confusion and require subsequent  
 25 determination of how much (6R) isomer need be present to indeed be "non-negligible."

1 Additionally, contrary to Defendant's assertions, the omission of "non-negligible" from the  
 2 construction of "mixture" does not expand the claim scope to cover "pure" (6S) isomer because  
 3 a mixture of the two isomers cannot exist if one of the isomers is completely absent. The very  
 4 term "mixture" requires that each isomer be present in the composition in some detectable  
 5 amount.

6 Having provided no additional basis for the inclusion of the "non-negligible" language in  
 7 the construction of "mixture," the Court finds that Defendant has failed to provide language  
 8 from the specification of the '829 Patent that would require such a limitation. Therefore, the  
 9 Court declines to adopt this portion of Defendant's proposed construction.

10       b.    *"two-component combination"*

11       Defendant also argues that the Court should limit the claimed "mixture" to a "two-  
 12 component combination" because "in a patent claim, the transitional phrase 'consists of'  
 13 signifies the exclusion of any ingredient not specified in the claim and the asserted claims  
 14 describe two components, (6S) and (6R) leucovorin." (Resp. 6:18–21 (citing *In re Crish*, 393  
 15 F.3d 1253, 1257 (Fed. Cir. 2004).) Plaintiffs, on the other hand, argue that neither the claim  
 16 language nor the words of the remainder of the specification support Defendant's construction.  
 17 (Pls.' Br. 13:20–24.)

18       In *Crish*, the Federal Circuit examined three claims that contained the phrase "consists  
 19 of" within the body of the claim. 393 F.3d at 1254–55:

20       Claims 53–55 on appeal are all independent and read as follows:

21       53. A purified oligonucleotide comprising at least a portion of the nucleotide  
 22 sequence of SEQ ID NO:1, wherein said portion consists of the nucleotide  
sequence from 521 to 2473 of SEQ ID NO:1, and wherein said portion of the  
 23 nucleotide sequence of SEQ ID NO:1 has promoter activity.

24       54. A purified oligonucleotide comprising at least a portion of the nucleotide  
 25 sequence of SEQ ID NO:1, wherein said portion consists of the nucleotide  
sequence from 1141 to 2473 of SEQ ID NO:1, and wherein said portion of the  
 nucleotide sequence of SEQ ID NO:1 has promoter activity.

1       55. A purified oligonucleotide comprising at least a portion of the nucleotide  
 2       sequence of SEQ ID NO:1, wherein said portion consists of the nucleotide  
3       sequence from 1488 to 2473 of SEQ ID NO:1, and wherein said portion of the  
 4       nucleotide sequence of SEQ ID NO:1 has promoter activity.

5       *Id.* (emphasis added). Based on this claim language, the Federal Circuit held that “the term  
 6       ‘consists’ limits the ‘said portion’ language to the subsequently recited nucleotides.”  
 7       Furthermore, in the relevant claim language, the “said portion” language was located before the  
 8       “consists of” language that acted to limit “said portion” to the subsequently stated nucleotide  
 9       sequence. *Id.* at 1254–55.

10      In the instant case, the claim language of the ’829 Patent is distinguishable and, thus,  
 11     does not warrant the same conclusion that the Federal Circuit reached in *Crish*. Contrary to  
 12     Defendant’s assertion that the term “consists of” limits the term “a mixture,” the term “consists  
 13     of” appears after the term “the compound.” ’829 Patent col.9 ll.62–64. Thus, “consists of”  
 14     actually limits “the compound,” and not “the mixture.” *Id.* Accordingly, the Court is not  
 15     persuaded that *Crish* requires the term “mixture” to be limited to a “two-component  
 16     combination.”

17      Having provided no additional basis for the inclusion of the “two-component  
 18     combination” language in the construction of “mixture,” the Court finds that Defendant has  
 19     failed to provide the Court with language from the specification of the ’829 Patent that would  
 20     require such a limitation. Therefore, the Court declines to adopt this portion of Defendant’s  
 21     proposed construction.

### 22           3. *The Court’s Construction*

23      After looking first to the words of the claim and then the remaining parts of the  
 24     specification, the Court finds that a person of ordinary skill in the art of organic chemistry would  
 25     understand the ’829 Patent to use the term “mixture” in accordance with that phrase’s plain  
 26     meaning. This phrase needs no further construction.

## B. The “Percentage” Claim Terms

Proposed Constructions		
“consists of (at least 92%)(at least about 92%)(at least about 95%) by weight of the (6S) diastereoisomers”	Spectrum	“contains (92% or more)(about 92% or more)(greater than 95%) by weight of the (6S) diastereomer”
	Sandoz	“the [compound] consists of (6S) diastereoisomers with diastereomeric purity of (at least 92%)(at least about 92%)(greater than 95%) by weight and up to 98% by weight”
“said mixture of (6S) and (6R) diastereoisomers consist of (at least about 92%)(at least about 95%) by weight of the (6S) diastereoisomers”	Spectrum	“the mixture of (6S) and (6R) diastereoisomers of leucovorin contains (about 92% or more)(about 95% or more) by weight of the (6S) diastereoisomers”
	Sandoz	“the two-component combination consisting of non-negligible amounts of (6R) diastereoisomers and (6S) diastereoisomers with diastereomeric purity (at least about 92%)(at least about 95%) by weight and up to 98% by weight”

Some form of these “percentage” claim terms appears in Claims 1, 2, 5, 7, 10, and 12.

## **1. Defendant's Proposed Construction**

Defendant’s proposed construction amounts to an upper limit on the purity of the compound claimed in the ’829 Patent. Defendant asserts that its proposed construction “define[s] [an] upper limit, and do[es] so by reference to the specification and the prosecution history, including the inventor’s own declarations, and arguments the applicants made in order to obtain allowance of the ’829 patent.” (Resp. 14:22–24, ECF No. 53.)

Specifically, Defendant argues that the '829 Patent should be limited to a compound containing at most 98% by weight (6S) diastereoisomer. Defendant supports its proposed construction with Example 1 in the written description, which describes a butanol extraction that yields a mixture with 91% and 92% purity of the (6S) diastereoisomer. '829 Patent col.6, 1.51–col.7 1.10. Defendant further asserts that repeated rounds of butanol extractions would not lead

1 to any significant increase in purity and, thus, an upper limit must be imposed on the percentage  
2 claim terms. Defendant further argues that such an upper limit is warranted because the  
3 separation method described in the specification of the '829 Patent could not achieve greater  
4 than a 98% pure (6S) diastereoisomer composition.

5 These arguments are unavailing. First, the Court finds no support for Defendant's  
6 proposed construction in the intrinsic evidence. In fact, *Phillips* instructs that a court should  
7 look to the words of the claims themselves when construing claim terms and, here, the words of  
8 the other claims in the '829 Patent contradict Defendant's proposed construction. Specifically,  
9 claim 4 expressly includes an upper limitation on the diastereomeric purity of the composition.  
10 '829 Patent, col.10 ll.7–9 (claiming a "pharmaceutical composition . . . which consists  
11 essentially of 92% to 95% by weight of the (6S) diastereoisomers"). The existence of an upper  
12 limit in one claim indicates that, if the patentee had intended to impose an upper limitation in the  
13 other claims, such an upper limit would also be stated explicitly in those other claims.

14 Additionally, adopting Defendant's proposed construction, which largely relies on  
15 Example 1, would result in the Court impermissibly limiting the '829 Patent to a preferred  
16 embodiment. *Phillips*, 415 F.3d at 1323 ("[W]e have expressly rejected the contention that if a  
17 patent describes only a single embodiment, the claims of the patent must be construed as being  
18 limited to that embodiment.").

19 Additionally, Defendant argues that its construction is consistent with the prosecution  
20 history of the '829 Patent. However, Defendant's arguments in support of its proposed  
21 construction are actually related to the defenses of lack of enablement and/or inadequate written  
22 description and are thus, improper at the claim construction stage of the litigation. Specifically,  
23 during prosecution, the USPTO rejected certain claims of the '829 Patent because the  
24 specification failed to enable compositions that were greater than 95% (6S) diastereoisomer. To  
25 overcome this lack of enablement rejection, one of the inventors, Dr. Suckling, submitted a

1 sworn declaration stating that “the purity . . . taking into account the intrinsic error is in the  
 2 range of about 90-98%.” (Keane Decl. Ex. 7, ECF No. 60; Jones Decl. ¶ 64, ECF No. 61.)  
 3 However, this statement alone is insufficient to amount to a disavowal of claim scope beyond  
 4 98% purity. Indeed, the Federal Circuit routinely “decline[s] to apply the doctrine of  
 5 prosecution disclaimer where the alleged disavowal of claim scope is ambiguous.” *Omega*  
 6 *Eng’g, Inc. v. Raytek Corp.*, 334 F.3d 1314, 1324 (Fed. Cir. 2003) (reciting cases in which the  
 7 Federal Circuit has found the asserted disavowal too ambiguous to limit the scope of the claims).  
 8 In contrast, Dr. Suckling’s declaration was provided to the PTO merely to establish that the  
 9 specification adequately enabled the claims that recite purities above 95% (6S) diastereoisomer.  
 10 Accordingly, the Court finds that Defendant has failed to cite language in the file wrapper  
 11 amounting to an unambiguous statement disavowing all pharmaceutical compositions with  
 12 greater than 98% purity.

13 Defendant’s final argument relates to USPTO’s rejection in light of the prior art  
 14 reference, Rees 1986. In overcoming that rejection, the inventors distinguished their invention  
 15 to the USPTO as making “mixtures of (6S) and (6R) diastereoisomers,” and not pure (6S)  
 16 diastereoisomer as described in the Rees 1986 reference. (Keane Decl. Ex. 2, at 23, ECF No. 54-  
 17 2.) Defendant further asserts that “[a] person having ordinary skill in the art would understand  
 18 that the Rees 1986 product that the applicants disclaimed and described as “pure (6S)  
 19 diastereoisomer” in fact contained about 98% by weight (6S) diastereoisomer and 2% by weight  
 20 (6R) diastereoisomer.” (Jones Decl. ¶¶ 37–59, ECF No. 61.)

21 This argument is also unpersuasive because it is based on the extrinsic re-interpretation  
 22 by Defendant’s retained expert, Dr. Jones, of the underlying data supporting the Rees 1986  
 23 reference, rather than the words of the reference and how one of skill in the art would  
 24 understand those words. *See Phillips v. AWH Corp.*, 415 F.3d 1303, 1318 (Fed. Cir. 2005) (en  
 25 banc) (“[A] court should discount any expert testimony ‘that is clearly at odds with the claim

1 construction mandated by the claims themselves, the written description, and the prosecution  
 2 history, in other words, with the written record of the patent.” (internal quotations marks  
 3 omitted)). In fact, Dr. Jones, expressly admits that one of skill in the art would read the Rees  
 4 1986 reference as disclosing a product that is solely the (6S) diastereoisomer without the  
 5 presence of the (6R) diastereoisomer. (Antons Decl. Ex. 1 (Jones Dep. Tr.), at 6:11-23, ECF No.  
 6 82-1 (acknowledging that the authors of the Rees 1986 reference actually indicated that they  
 7 achieved a single product and that one of ordinary skill in the art would also understand that the  
 8 Rees 1986 reference disclosed a single product).) Nevertheless, Defendant’s retained expert  
 9 concludes that the Rees 1986 reference was incorrect when it concluded that the resulting  
 10 substance was a pure (6S) diastereoisomer product. However, Defendant and its retained expert  
 11 do not argue that one of skill in the art would read the words of the Rees 1986 reference as  
 12 disclosing a compound that contains 2% (6R) diastereoisomer. Rather, Defendant merely argues  
 13 that its expert disagrees with the conclusions made by the authors of the Rees 1986 reference.  
 14 Essentially, Defendant’s argument amounts to “second-guessing” the conclusions in the Rees  
 15 1986 reference and, thus, does not persuade the Court to adopt Defendant’s proposed  
 16 construction.

17 Even to the extent that there is a minor reference in a footnote of the Rees 1986 to a  
 18 compound containing small amounts of the (6R) diastereoisomer,<sup>3</sup> this reference does not rise to  
 19 the level of the unambiguous statement of disavowal required to establish a prosecution

---

20

21 <sup>3</sup> Defendant points out that, in a footnote, the Rees 1986 reference cited a 1983 article by Rees and a 1985 article  
 22 by Suckling. Defendant correctly notes that “[m]aterial not explicitly contained in [the prior art reference] may  
 23 still be considered . . . if that material is incorporated by reference into the document.” *Advanced Display Sys., Inc. v. Kent State Univ.*, 212 F.3d 1272, 1282 (Fed. Cir. 2000). However, merely citing an article in a footnote  
 24 does not result in that entire article being incorporated by reference to the later published article; before such an  
 25 article can be incorporated by reference, the later article “must identify with detailed particularity what specific  
 material it incorporates and clearly indicate where that material is found in the various documents.” *Id.*; *see also Commonwealth Scientific & Indus. Research Org. v. Buffalo Tech. (USA), Inc.*, 542 F.3d 1363, 1372 (Fed. Cir. 2008) (concluding that content from a reference that is merely cited in a footnote is not incorporated by reference  
 into the prior art reference because the prior art failed to “identify with detailed particularity what specific  
 material it incorporates and clearly indicate where that material is found in the various documents”).

1 disclaimer. *See Abbott Labs. v. Sandoz, Inc.*, 566 F.3d 1282, 1289 (Fed. Cir. 2009) (“Again  
 2 owing in part to the inherent ambiguities of prosecution history, the doctrine of prosecution  
 3 disclaimer only applies to unambiguous disavowals.”). As before, Defendant’s argument is  
 4 more appropriately raised in support of one of the various defenses to patent infringement.

5 Finally, the Federal Circuit has confronted similar language in the past and acknowledged  
 6 that “at least” limitations “set[] forth the minimum number of a particular element required.”  
 7 *Lantech Inc. v. Keip Mach. Co.*, 32 F.3d 542, 546 (Fed. Cir. 1994) (construing the term “at least  
 8 two” to “require two or more conveyor structures, not one”). Similarly, in *Quantum Corp. v.  
 9 Rodime, PLC*, the Federal Circuit expressly recognized that “‘at least 600 tpi’ . . . expressly  
 10 represents an open-ended range”). 65 F.3d 1577, 1581 (Fed. Cir. 1995). Thus, although the  
 11 requirement that this composition exist as a “mixture” of the two diastereoisomers eliminates the  
 12 possibility of the ’829 Patent covering a completely pure form of (6S) levoleucovorin, there is  
 13 no indication that the patent requires as much as 2% by weight of the undesirable (6R)  
 14 diastereoisomer.

15 **2. Plaintiffs’ Proposed Construction**

16 Plaintiffs contend that these “percentage” claim terms need no further construction. (See  
 17 Pls.’ Br. 6:16–17.) Essentially, Plaintiffs argue that these terms are clear on their face and, as a  
 18 result, no further understanding or explanation is needed. In response to Defendant’s Proposed  
 19 Construction, Plaintiffs assert that the imposition of an upper limit on the purity of the mixture  
 20 finds no support in the specification and, in fact, contradicts the language of the written  
 21 description. Specifically, Plaintiffs note that the ’829 patent “teaches that when a very high  
 22 percentage of the (6S) isomer is desired, the crystallization (shown above as a ‘butanol  
 23 extraction’) can be repeated over and over until the desired percentage is obtained: ‘Where  
 24 appropriate more than one solvent extraction or fractional crystallisation step may be carried out  
 25 in order to improve purity.’” (Pls.’ Br. 8:5–9, ECF No. 49 (citing ’829 Patent col.3 ll.54–56).)

1 The patent further teaches that “the [solvent extraction or fractional crystallisation] step may be  
 2 repeated until the recovered new diastereoisomers has a purity greater than 90%.” ’829 Patent  
 3 col.3, ll.56–58. Plaintiff asserts that, from this, one of skill in the art would know that  
 4 “subsequent rounds of separation would improve the 91%-pure mixture to 99%-pure mixture or  
 5 higher.” (Pls.’ Br. 8:13–15, ECF No. 49 (citing Reider Decl. ¶ 25, ECF No. 51).)

6 The Court agrees with Plaintiffs that the upper limit that Defendant would impose in this  
 7 claim language is supported by neither the intrinsic evidence nor the Federal Circuit’s precedent.  
 8 *See Lantech Inc. v. Keip Mach. Co.*, 32 F.3d 542, 546 (Fed. Cir. 1994) (construing the term “at  
 9 least two” to “require two or more conveyor structures, not one”). The Court also agrees that  
 10 this is not the type of “terse claim language” that needs elaboration to allow the factfinder to  
 11 understand the scope of the claims. *See Terlep v. Brinkmann Corp.*, 418 F.3d 1379, 1382 (Fed.  
 12 Cir. 2005).

13 **3. The Court’s Construction**

14 After looking first to the words of the claim and then the remaining parts of the  
 15 specification, the Court finds that a person of ordinary skill in the art of organic chemistry would  
 16 understand the ’829 Patent to use these “percentage” claim terms in accordance with their plain  
 17 meaning. These phrases need no further construction.

18 **C. “the balance of said composition consisting of the (6R) diastereoisomer”**

<b>Spectrum</b>	“the remaining amount of the mixture of (6S) and (6R) diastereomers is the (6R) diastereoisomer, and any impurities normally associated with the mixture of (6S) and (6R) diastereomers”
<b>Sandoz</b>	“the balance of (the compound) (the composition) consists of a non-negligible amount of the (6R) diastereoisomer”

22 This phrase appears in claims 1, 5, 7, 10 and 12.

23 **I. The Parties’ Proposed Constructions**

24 In the claims of the ’829 Patent, this phrase follows the previously discussed “mixture”  
 25 and “percentage” claim terms and recites that the portion of the mixture that does not consist of

1 the desired (6S) diastereoisomer, consists of (6R) diastereoisomer. Along with many other  
 2 disputed claim terms in the '829 Patent, this claim term also requires that both the (6S) and (6R)  
 3 diastereoisomer are present in the claimed "pharmaceutical composition"; the '829 Patent does  
 4 not cover a composition that consists solely of the (6S) diastereoisomer. Plaintiffs' proposed  
 5 construction is consistent with this plain meaning.

6 Plaintiffs also assert that the balance of the composition that is not (6S) diastereoisomer  
 7 may also consist of "any impurities normally associated with the mixture of (6S) and (6R)  
 8 diastereomers." After reviewing Defendant's Responsive Claim Construction Brief, it appears  
 9 to the Court that Defendant does not dispute this portion of Plaintiff's proposed construction.  
 10 (See Resp. 6:18–7:6, ECF No. 53.) Indeed, both parties cite to *Conoco, Inc. v. Energy & Envtl.*  
 11 *Int'l*, in which the Federal Circuit held that the transitional phrase "consisting of," closes the  
 12 claim "to the inclusion of materials other than those recited except for impurities ordinarily  
 13 associated therewith." 460 F.3d 1349, 1360 (Fed. Cir. 2006) ("[I]mpurities that a person of  
 14 ordinary skill in the relevant art would ordinarily associate with a component on the 'consisting  
 15 of' list do not exclude the accused product or process from infringement.") In its brief,  
 16 Defendant explains that, because its proposed construction retained the "consists of" language,  
 17 this additional language in the construction was unnecessary. However, given that the Federal  
 18 Circuit has already endorsed this definition, the Court will adopt this portion of Plaintiffs'  
 19 proposed construction to provide further guidance to the factfinder.

20 Finally, in Defendant's proposed construction, Defendant, once again, inserts "non-  
 21 negligible" into the construction. For the reasons previously stated in Section V.A.2.a, the Court  
 22 declines to adopt Defendant's "non-negligible" construction.

23 **2. The Court's Construction**

24 After looking first to the words of the claim and then the remaining parts of the  
 25 specification, the Court finds that a person of ordinary skill in the art of organic chemistry would

1 understand the '829 Patent to use the phrase "the balance of said compound consisting of the  
 2 (6R) diastereoisomer" as meaning "the remaining amount of the mixture of (6S) and (6R)  
 3 diastereoisomers is the (6R) diastereoisomer, and any impurities normally associated with the  
 4 mixture of (6S) and (6R) diastereoisomers."

5 **D. "Pharmaceutical composition for therapeutic use"**

<b>Spectrum</b>	"[A] pharmaceutical composition suitable for treating medical conditions"
<b>Sandoz</b>	"[A] pharmaceutical composition in a final dosage form"

9 The preamble of both claim 1 and claim 5 recite "[a] pharmaceutical composition for  
 10 therapeutic use." The words of a claim's preamble do not always equate to claim limitations.  
 11 *See Am. Med. Sys., Inc. v. Biolitec, Inc.*, 618 F.3d 1354, 1359 (Fed. Cir. 2010) (concluding that  
 12 the preamble language "d[id] not constitute a limitation of the claims"); *see also Pitney Bowes,*  
 13 *Inc. v. Hewlett-Packard Co.*, 182 F.3d 1298, 1305 (Fed. Cir. 1999) (noting that the preamble is  
 14 "of no significance to claim construction [when] it cannot be said to constitute or explain a claim  
 15 limitation"). "In general, a preamble limits the invention if it recites essential structure or steps,  
 16 or if it is 'necessary to give life, meaning, and vitality' to the claim." *Catalina Mktg. Int'l, Inc. v.*  
 17 *Coolsavings.com, Inc.*, 289 F.3d 801, 808 (Fed. Cir. 2002) (quoting *Pitney Bowes*, 182 F.3d at  
 18 1305). Here, the parties agree that the preamble language, "a pharmaceutical composition for  
 19 therapeutic use," imposes a limitation on claims 1, 5, and the claims that depend therefrom.  
 20 (Pls.' Br. 18, n.64, ECF No. 49.)

21 **1. Defendant's Proposed Construction**

22 Defendant proposes that the Court construe the phrase "pharmaceutical composition for  
 23 therapeutic use" as "a composition in a final dosage form." (Resp. 15:1–8, ECF No. 53.)  
 24 Defendant contends that this construction is consistent with the claim language, the words of the  
 25 other claims and the words of the written description. (*Id.* at 15:18–17:18.) In contrast,

1 Plaintiffs argue that Defendant's proposed construction is actually inconsistent with the  
2 specification, violates the doctrine of claim differentiation, and excludes a preferred  
3 embodiment. (Reply 14:12–15:19, ECF No. 56.)

4 Defendant first supports its proposed construction by relying on the words of independent  
5 claims 1 and 5 and the differences between those claims and independent claim 10. Both claims  
6 1 and 5 recite a pharmaceutical composition that is used “in combination with a  
7 pharmaceutically acceptable carrier.” In contrast, claim 10 omits any reference to a carrier and,  
8 instead, appears to be related to a bulk drug product that can later be used to prepare a  
9 medication that can be combined with a carrier. *See '829 Patent col.10 ll.47–62 (Claim 10)*  
10 (claiming “[a] pharmaceutical composition for preparing medicaments for therapeutic use . . .”).  
11 Based on these differences, Defendant asserts that the pharmaceutical composition claimed in  
12 Claims 1 through 9 must claim a pharmaceutical product in “a final dosage form” that is  
13 “formulated for administration to patients.” (Resp. 15:1–12.)

14 Furthermore, the Court need not include the “final dosage form language” in this  
15 construction to differentiate claims 1 through 9 from claims 10 through 14; the existing words of  
16 these claims are sufficient. Specifically, claims 1, 5 and the claims that depend therefrom  
17 expressly recite a “pharmaceutical composition for therapeutic use . . . *in combination with a*  
18 *pharmaceutically acceptable carrier.*” *See, e.g., '829 Patent col.9 ll.55–67 (Claim 1)* (emphasis  
19 added). In contrast, claim 10 and those claims that depend therefrom omit any reference to such  
20 a pharmaceutically acceptable carrier and, instead, recite “[a] pharmaceutical composition *for*  
21 *preparing medicaments* for therapeutic use in the treatment of human beings.” *'829 Patent*  
22 *col.10 ll.47–62 (Claim 10)* (emphasis added). Thus, the distinction on which Defendant relies is  
23 already present in the language of the claims of the '829 Patent. The addition of “final dosage  
24 form” would result in the Court imposing an additional limitation that is not required by the  
25 claim language.

Even if Defendant's proposed construction was reasonable based solely on the words of the claims, this construction cannot survive a review of the rest of the specification. Defendant argues that the specification does support its proposed construction because the specification lists "suitable formulations" such as "injectable solutions; powders for injection . . . ; and tablets." (Resp. 16:9–10 (omission in original).) However, Defendant's Response Brief omits, by way of ellipses, the complete description of the "powders for injection" preferred embodiment. (See *id.*) Specifically, the specification states that "powders for injection" are actually "powders for injection, *which may be reconstituted shortly before use by addition of Water for injection.*" '829 Patent col.5 ll.12–15 (emphasis added). Thus, not all "suitable formulations" are actually in a final form that can be administered to a patient; the "powder for injection" formulation requires additional steps before it can be injected into a patient. Not only is Defendant's proposed construction inconsistent with the specification, but it would also exclude this preferred embodiment. *See Vitronics Corp. v. Conceptronic, Inc.*, 90 F.3d 1576, 1583 (Fed. Cir. 1996) (stating that a construction that excludes a preferred embodiment "is rarely, if ever, correct").

For these reasons, the Court declines to adopt Defendant's proposed construction.

## **2. Plaintiffs' Proposed Construction**

In contrast to Defendant's proposed construction, Plaintiffs' proposed construction is consistent with both the words of the claims and with the words of the specification. Specifically, Plaintiffs' propose that the Court construe the phrase "pharmaceutical composition for therapeutic use" as "pharmaceutical composition for treating medical conditions."

Because Plaintiffs' proposed construction is consistent with the specification, the Court will adopt Plaintiff's proposed construction. Specifically, the specification discloses that this "pharmaceutical composition" can be used as "a rescue agent to counteract the action of DHFR inhibitors such as methotrexate"; it can be used "in the treatment of folate deficiency"; and,

1 finally, it “may be used in combination with 5-fluorouracil in the treatment of colorectal  
 2 cancer . . .” ’829 Patent col. 4, 1.64–col.5, 1.2. Accordingly, the specification expressly  
 3 acknowledges that the claimed pharmaceutical composition is used to treat medical conditions.

4 **3. The Court’s Construction**

5 For the reasons stated above, after looking first to the words of the claim and then the  
 6 remaining parts of the specification, the Court finds that a person of ordinary skill in the art of  
 7 organic chemistry would understand the ’829 Patent to use the term “pharmaceutical  
 8 composition for therapeutic use” as “a pharmaceutical composition suitable for treating medical  
 9 conditions.”

10 **E. “Pharmaceutical composition for preparing medicaments for therapeutic use  
 11 for the treatment of human beings”**

12 **Proposed Constructions**

<b>Spectrum</b>	“[A] pharmaceutical composition from which can be prepared a medicine suitable for treating medical conditions in human beings”
<b>Sandoz</b>	“[A] pharmaceutical composition for preparing a final dosage form”

13 Much of the reasoning that applies to the construction of the phrase “[a] pharmaceutical  
 14 composition for therapeutic use” also applies to the related phrase, “[a] pharmaceutical  
 15 composition for preparing medicaments for therapeutic use in the treatment of human beings.”  
 16 Similar to Defendant’s proposed construction in Section V.C.1, Defendant argues that this claim  
 17 phrase also relates to “a final dosage form,” specifically, to “a pharmaceutical composition *for*  
 18 *preparing* a final dosage form.” (Resp. 17:16–18, ECF No. 53.) However, for the reasons  
 19 discussed above in Section V.C, the Court declines to include the “final dosage form” in its  
 20 construction of this phrase. Also, for the reasons discussed above in Section V.C, the Court  
 21 agrees with Plaintiffs’ proposed construction.  
 22  
 23

24    ///

25    ///

1                   **I. The Court's Construction**

2                   Thus, after looking first to the words of the claim and then the remaining parts of the  
 3 specification, the Court finds that a person of ordinary skill in the art of organic chemistry would  
 4 understand the '829 Patent to use the term "pharmaceutical composition for preparing  
 5 medicaments for therapeutic use in the treatment of human beings" as "a pharmaceutical  
 6 composition from which can be prepared a medicine suitable for treating medical conditions in  
 7 human beings."

8                   **F. The "pharmaceutically acceptable" Claim Terms**

9                   **Proposed Constructions**

<b>"a pharmaceutically acceptable compound"</b> <b>(claim 1)</b>	<b>Spectrum</b>	"a compound suitable for treating medical conditions which is not harmful to the recipient thereof"
	<b>Sandoz</b>	Plain Meaning
<b>"a pharmaceutically acceptable composition"</b> <b>(claim 5)</b>	<b>Spectrum</b>	"a composition suitable for treating medical conditions which is not harmful to the recipient thereof"
	<b>Sandoz</b>	Plain Meaning
<b>"a pharmaceutically acceptable carrier"</b> <b>(claim 1, 5)</b>	<b>Spectrum</b>	"a solid or liquid diluent that is compatible with the other ingredients of the formulation and is not harmful to the recipient thereof"
	<b>Sandoz</b>	Plain Meaning

18                   A version of this claim term appears in independent claim 1 and independent claim 5.

19                   **I. The Parties' Proposed Constructions**

20                   Although Defendant initially requested that the Court construe this term, (see Antons  
 21 Decl. Ex.3, at 1, ECF No. 50-3), Defendant asserts that the Court should give this term its plain  
 22 meaning.<sup>4</sup>

23                   // /

24

---

25                   <sup>4</sup> Defendant has not provided the court with an explanation why it would request construction of a term and then simply assert that, essentially, no construction is required because the term should be given its plain meaning.

1 Plaintiffs, on the other hand, contend that for a compound/composition/carrier to be  
2 “pharmaceutically acceptable,” it must be “suitable for treating medical conditions” and “not  
3 harmful to the recipient thereof.” To support its proposed construction, Plaintiff provides only  
4 one citation to the intrinsic record. (Pls.’ Br. 26:21–25, ECF No. 49.) The specification of the  
5 ’829 Patent explains that this compound “may be used as a rescue agent to counteract the action  
6 of DHFR inhibitors such as methotrexate. It may also be used in the treatment of folate  
7 deficiency. In addition it may be used in combination with 5-fluorouracil in the treatment of  
8 colorectal cancer.” ’829 Patent col.4 1.64–col.5 1.4. This section of the written description does  
9 indicate that the intended purpose of the claimed compound is to treat human ailments.  
10 However, this section does not support a construction that would exclude all compounds that  
11 cause any harm to patients because, as Defendant notes, all pharmaceuticals have potential  
12 negative side effects. Furthermore, the Federal Circuit has previously rejected similar  
13 arguments in the context of pharmaceutical patents. *Aventis Pharma S.A. v. Hospira, Inc.*, 675  
14 F.3d 1324, 1330 (Fed. Cir. 2012) (declining to construe “suitable for infusion into patients” to  
15 include “efficacy, safety, and stability limitations” because the intrinsic record lacked support  
16 for such a construction”). Additionally, because of the inherent side effects, adopting Plaintiffs’  
17 proposed construction would only introduce further ambiguity into the scope of this claim term.  
18 Therefore, the Court will not adopt Plaintiffs’ proposed “not harmful to the recipient”  
19 construction.

20 **2. The Court’s Construction**

21 “The construction of claims is simply a way of elaborating the normally terse claim  
22 language in order to understand and explain, but not to change, the scope of the claims.” *Terlep*,  
23 418 F.3d at 1382. Furthermore, when the claim language is “clear on its face,” then the Court’s  
24 “consideration of the rest of the intrinsic evidence is restricted to determining if a deviation from  
25 the clear language of the claims is specified.” *Interactive Gift Exp.*, 256 F.3d at 1331. The

1 language of this disputed claim term is certainly clear on its face. Thus, after looking first to the  
 2 words of the claim and then the remaining parts of the intrinsic record, the Court finds that a  
 3 person of ordinary skill in the art of organic chemistry would understand the phrase  
 4 “pharmaceutically acceptable,” as used in the’829 Patent, to have its plain and ordinary  
 5 meaning. For these reasons, the Court finds that this phrase, as used in claims 1 and 5, requires  
 6 no further construction.

7 **G. “consists essentially of”**

8 **Proposed Constructions**

<b>Spectrum</b>	includes the following components, as well as components that do not materially affect the basic and novel characteristics of the claimed composition (such as impurities that do not impact the efficacy of the composition)
<b>Sandoz</b>	The specified materials and those that do not materially affect the basic and novel characteristic(s) of the composition

13 The phrase “consists essentially of” appears in Claim 1. Both parties acknowledge that  
 14 the Federal Circuit has already determined that this term has an established meaning. (See Pls.’  
 15 Br. 27:4–16, ECF No. 49; Resp. 26:4–19, ECF No. 53.) “By using the term ‘consisting  
 16 essentially of,’ the drafter signals that the invention necessarily includes the listed ingredients  
 17 and is open to unlisted ingredients that do not materially affect the basic and novel properties of  
 18 the invention.” *PPG Indus. v. Guardian Indus. Corp.*, 156 F.3d 1351, 1354 (Fed. Cir. 1998).  
 19 The “consisting of” transition phrase also permits “the inclusion of . . . impurities ordinarily  
 20 associated with [the materials recited in the claim].” *Conoco, Inc. v. Energy & Envtl. Int’l, L.C.*,  
 21 460 F.3d 1349, 1360 (Fed. Cir. 2006).

22 **1. The Parties’ Proposed Constructions**

23 Defendant simply requests that the Court construe this term in accordance with the well-  
 24 established Federal Circuit case law discussed above. In contrast, although Plaintiff agrees that  
 25 the Federal Circuit’s endorsed definition of “consists essentially of” applies to claim 1 of the

1 '829 Patent, Plaintiff asserts that "the file history [of the '829 Patent] adds to this definition.  
2 (Pl.'s Br. 27:9–16, ECF No. 49.) Specifically, Plaintiff asserts that the proper construction of  
3 this term would also expressly state that any "impurities that do not impact the efficacy of the  
4 composition" may also be present in the claimed pharmaceutical composition. (*Id.* at 27:13–16.)  
5 Plaintiff supports this assertion by relying on an Appeal Brief submitted during prosecution  
6 which provides:

7 The term "consists essentially of" has a well-known meaning in patent law; see  
8 e.g., MPEP § 2111.03 (The scope of the claim is limited "to the specified materials  
9 or steps 'and those that do not materially affect the basic and novel  
characteristic(s)'".)

10 It is apparent that these claims are directed to compositions in which the (6R)  
11 diastereoisomer is present in the specified amount; and that, for example, excess  
12 (6R) diastereoisomer would be excluded as would be additives destroying  
pharmaceutical purity.

13 (Antons Decl. Ex. 6, at 20, ECF No. 50-6.) Plaintiffs argue that this passage supports their  
14 construction because

15 [t]he example provided to the examiner was in the form of what would be  
16 excluded. Plaintiffs' construction incorporates this language that impurities  
17 ("additives") are permitted as long as those impurities do not increase the recited  
amount of the (6R) diastereoisomer or impact the efficacy of the composition  
("destroying pharmaceutical purity").

18 (Pls.' Br. 28:2–6.)

19 The Court disagrees that this portion of the prosecution history warrants the construction  
20 that Plaintiffs request. First, this section of the appeal brief solely recognizes that many of the  
21 claims list a specific amount of the (6R) diastereoisomer that must be present and that a  
22 pharmaceutical composition that included an amount of the (6R) diastereoisomer in excess of  
23 those specified amounts would not be covered by the claims of the '829 Patent. Implying from  
24 this language that other impurities would be covered by the claims is a leap that the Court is  
25 neither willing nor required to make. In fact, the Federal Circuit has expressly noted that when

1 the specification is silent as to the effect of a given component, whether the presence of that  
 2 additional component has a “material effect” on the claimed invention is not a matter of claim  
 3 construction but is, instead, an issue for the factfinder as part of its infringement determination.  
 4 *See, e.g., PPG Indus.*, 156 F.3d at 1354–55.

5 Here, the Court does not doubt that there are certain impurities that are “ordinarily  
 6 associated” with the claimed composition that would be covered by the’829 Patent. *See Conoco,*  
 7 *Inc.*, 460 F.3d at 1360 (“[I]mpurities that a person of ordinary skill in the relevant art would  
 8 ordinarily associate with a component on the ‘consisting of’ list do not exclude the accused  
 9 product or process from infringement.”). However, the parties have not pointed to any specific  
 10 impurity. As such, the Court is unable to determine whether the specification contemplates  
 11 whether these impurities would have a material effect on the claimed composition.  
 12 Furthermore, Plaintiffs have failed to provide the Court with any reference to the specification  
 13 from which the Court could determine whether the general category of “impurities” has a  
 14 material effect. Accordingly, the Court declines to adopt Plaintiffs’ requested construction and  
 15 will leave the question of whether a given impurity, that will presumably be identified at trial,  
 16 has a material effect on the claimed composition such that the presence of that impurity in an  
 17 accused composition renders that accused composition non-infringing.

18 **2. *The Court’s Construction***

19 After looking first to the words of the claim and then the remaining parts of the  
 20 specification, the Court finds that a person of ordinary skill in the art of organic chemistry would  
 21 understand the’829 Patent to use the phrase “consists essentially of” as meaning “the specified  
 22 materials and those that do not materially affect the basic and novel characteristic(s) of the  
 23 composition.”

24     ///

25     ///

1        H.     The “Multiple Dose” or “4,000 mg (4 grams)” Claim Terms<sup>5</sup>

Proposed Constructions		
“said composition being of a quantity at least sufficient to provide multiple doses of said mixture of (6S) and (6R) diastereoisomers in an amount of 2000 mg per dose” (claim 5)	<b>Spectrum</b>	“the pharmaceutically acceptable composition is present in the claimed pharmaceutical composition in an amount of 4,000 mg or more”
	<b>Sandoz</b>	“the composition being present in a final unit dosage form in an amount sufficient to provide multiple doses of the two-component combination of non-negligible amounts of each of the (6S) and (6R) diastereoisomers”  The “multiple dose” claim terms should retain the “per dose” limitation
“said mixture of (6S) and (6R) diastereoisomers being present in said pharmaceutical composition in an aggregate quantity at least sufficient to provide multiple doses of said mixture in an amount of 2000 mg per dose” (claim 10)	<b>Spectrum</b>	“the mixture of (6S) and (6R) diastereoisomers of leucovorin is present in the claimed pharmaceutical composition in an amount of 4,000 mg or more”
	<b>Sandoz</b>	“a total amount of the two-component combination consisting of non-negligible amounts of each of the (6S) and (6R) diastereoisomers, sufficient to provide multiple doses of the two-component combination”  The “multiple dose” claim terms should retain the “per dose” limitation

Some form of these “4,000 mg (4 grams)” or “multiple dose” claim terms appears in independent claims 5 and 10.

21        ***1. The Parties’ Proposed Constructions***

22        Plaintiffs urge the Court to construe these claims to require that the mixture of (6S) and (6R) diastereoisomers is present in an amount of at least 4,000 mg. In response, Defendant first asserts that Plaintiffs’ proposed construction would impermissibly eliminate the requirement

25        <sup>5</sup> Plaintiffs refer to this group of claim terms as the “4,000 mg (4 grams)” claim terms, (see Pls.’ Br. 28:8), and Defendant refers to this group of claim terms as the “multiple dose” claim terms, (see Resp. 22:22–23).

1 that the mixture be present in an amount of at least 2,000 mg *per dose*. Defendant also  
2 incorporates the “final dosage form” and the “non-negligible” language into its proposed  
3 constructions. As discussed above, the Court finds that the intrinsic record does not support the  
4 inclusion of these phrases. Thus, the Court will not adopt the portions of Defendant’s proposed  
5 constructions that incorporates these phrases.

6 However, the Court also concludes that Plaintiffs’ proposed construction is improper  
7 because it impermissibly ignores the “per dose” limitation recited in claims 5, 10 and the claims  
8 that depend therefrom. Plaintiffs contend that providing “multiple doses” of the mixture “in an  
9 amount of 2000 mg per dose” necessarily requires that the claimed composition contain, at  
10 minimum, 4,000 mg of the (6S) and (6R) mixture. (Pls.’ Br. 28:20–29:2, ECF No. 49.)  
11 Plaintiffs argue that their proposed construction merely “incorporate[s] [the “2000 mg per dose”  
12 limitation] into their proposed construction with an explicit requirement that the claimed  
13 composition must contain 4,000 milligrams or more of the (6S)/(6R) mixture.” (Reply 19:24–  
14 20:2, ECF No. 56.)

15 Plaintiffs also attempt to rely on the prosecution history to further support their proposed  
16 construction. True enough, during the prosecution of the ’829 Patent, the inventors stated that  
17 the claims required a minimum of four grams of the (6S)/(6R) mixture. (Antons Decl. Ex. 6, at  
18 26, ECF No. 50-6.) Despite Plaintiffs’ arguments to the contrary, these statements in the  
19 prosecution history cannot overcome the words of claims 5 and 10. *See Phillips*, 415 F.3d at  
20 1317 (cautioning that the prosecution history “often lacks the clarity of the specification and  
21 thus is less useful for claim construction purposes”). This prosecution history argument is also  
22 unpersuasive in light of the differences between the words of independent claims 5 and 10 and  
23 dependent claims 6 and 11. *See id.* at 1314 (“Other claims of the patent in question, both  
24 asserted and unasserted, can also be valuable sources of enlightenment as to the meaning of a  
25 claim term.”). Specifically, both claims 6 and 11 expressly state that the “mixture of (6S) and

1 (6R) diastereoisomers is present in said composition in an amount of at least about 10 grams.”  
2 ’829 Patent col.10 ll.25–28 (Claim 6), col.10 ll.63–67 (Claim 11). If the inventors had wanted  
3 claims 5 and 10 to incorporate a minimum of 4000 mg, or 4 grams, the inventors could have  
4 worded claims 5 and 10 similarly to claims 6 and 11. In light of the applicant’s decision to  
5 incorporate different words in these claims, the language of Claims 6 and 11 establish that a  
6 proper construction of this claim term must retain the “per dose” language.

7 **2. The Court’s Construction**

8 As discussed above, the Court concludes that neither party has provided a correct  
9 construction for this disputed claim term. “The construction of claims is simply a way of  
10 elaborating the normally terse claim language in order to understand and explain, but not to  
11 change, the scope of the claims.” *Terlep*, 418 F.3d at 1382. Furthermore, when the claim  
12 language is “clear on its face,” then the Court’s “consideration of the rest of the intrinsic  
13 evidence is restricted to determining if a deviation from the clear language of the claims is  
14 specified.” *Interactive Gift Exp.*, 256 F.3d at 1331. The language of this disputed claim term is  
15 certainly clear on its face. This phrase merely calls for a pharmaceutical composition capable of  
16 providing two or more doses of the claimed mixture of (6S) and (6R) diastereoisomers in an  
17 amount of 2000 mg, or two grams, at minimum, per dose. In contrast, claim 10 provides that the  
18 pharmaceutical composition must contain a sufficient amount of the (6S) and (6R) mixture to  
19 provide “at least” 2000 mg, or two grams, per dose.

20 Thus, after looking first to the words of the claim and then the remaining parts of the  
21 intrinsic record, the Court finds that a person of ordinary skill in the art of organic chemistry  
22 would understand the phrase “said composition being of a quantity at least sufficient to provide  
23 multiple doses of said mixture of (6S) and (6R) diastereoisomers in an amount of 2000 mg per  
24 dose,” as used in the’829 Patent, to have its plain and ordinary meaning. The words of the  
25 claims and the remaining parts of the specification do not support the construction asserted by

either party. Rather, “said composition being of a quantity at least sufficient to provide multiple doses of said mixture of (6S) and (6R) diastereoisomers in an amount of 2000 mg per dose” simply requires that the pharmaceutical composition contains enough of the (6S)/(6R) mixture to provide two or more doses of, at minimum, 2000 mg per dose of the mixture. For these reasons, the Court finds that this phrase, as used in claims 5 and 10, requires no further construction.

**I. Preamble of Claim 13: “The pharmaceutical composition for therapeutic use for the treatment of human beings prepared from the composition of claim 11”**

**Proposed Constructions**

<b>Spectrum</b>	“A composition suitable for treating medical conditions in human beings prepared from the composition recited in claim 11”
<b>Sandoz</b>	This term improperly depends from claim 11

**1. *Claims 13 and 14 are both dependent claims.***

The Patent Act permits applicants to draft a claim that incorporates by reference all the limitations from a previously stated claim, but requires that this “dependent” claim must further narrow the scope of the claim from which the claim depends. 35 U.S.C. § 112(d) (“[A] claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.”) The Federal Circuit has instructed that “[t]o establish whether a claim is dependent upon another, [courts] examine[] if the new claim both refers to an earlier claim and further limits that referent.” *Monsanto Co. v. Syngenta Seeds, Inc.*, 503 F.3d 1352, 1357 (Fed. Cir. 2007) (citing 35 U.S.C. § 112(d)). However, when engaging in this analysis, courts must be mindful that “[a] claim’s status as dependent or independent depends on the substance of the claim in light of the language of § 112, ¶ 4, and not the form alone.” *Id.* at 1357–58.

Here, Plaintiffs argue that both claim 13 and claim 14 are independent claims, despite the references to claim 11 and claim 10, respectively. Plaintiffs contend that these claims simply

1 “incorporate[] the composition claim[s] by reference, thereby avoiding having to rewrite all of  
 2 the limitations in claims 10 and 11.” (Pls.’ Br. 21:11–14, ECF No. 49.) In contrast, Defendant  
 3 asserts that the Court should construe these terms as dependent claims because claim 13 refers to  
 4 claim 11 and claim 14 refers to claim 10.

5       Although not cited by the parties, the Court finds the Federal Circuit’s decision in  
 6 *Monsanto Co. v. Syngenta Seeds, Inc.* particularly instructive on this issue. In *Monsanto Co. v.*  
 7 *Syngenta Seeds, Inc.*, the Federal Circuit was confronted with whether a claim was a dependent  
 8 or an independent claim when the claim referred to another claim and was written “in a  
 9 somewhat unusual format.” 503 F.3d at 1357–58. Specifically, claim 4 recited: “A process  
 10 comprising obtaining progeny from a fertile transgenic plant *obtained by the process of claim 1*  
 11 which comprise said DNA.” *Id.* at 1355 (quoting United States Patent No. 5,538,880 (filed May,  
 12 26, 1994)). Despite the plaintiff’s urging to the contrary, the Federal Circuit concluded that  
 13 claim 4 depended from claim 1 because the additional step that claim 4 added could be  
 14 performed only after the completion of the steps recited in claim 1. *Id.* at 1358 (“In other words,  
 15 the additional fourth step of obtaining progeny *depends* on the performance of the process  
 16 comprising the three steps recited in claim 1.”); *see also Maury Microwave, Inc. v. Focus*  
 17 *Microwaves, Inc.*, 10-cv-03902-MMM-JCGX, 2012 WL 9161988, at \*32–33 (C.D. Cal. July 30,  
 18 2012) (concluding that the claims that referred to another claim were dependent on the  
 19 referenced claim because the steps of the referenced claim had to be performed before the step  
 20 in the disputed claim could commence).

21       Claims 13 and 14 of the ’829 Patent are written in a similarly “unusual format.” Claim  
 22 13 of the ’829 Patent recites: “[A]<sup>6</sup> pharmaceutical composition for therapeutic use for the

---

23  
 24  
 25       <sup>6</sup> The originally issued claim 13 recited “*The pharmaceutical composition . . .*” ’829 Patent col.11 l.7 (emphasis  
 added). However, the ’829 Patent includes a Certificate of Correction, dated October 2, 2012, which provides  
 that claim 13 should recite “A pharmaceutical composition . . .”

1 treatment of human beings prepared from the composition of claim [11]<sup>7</sup> in a form selected from  
 2 the group consisting of injectable powers for injection which can be reconstituted shortly before  
 3 use by addition of water for injection; and tablets.” ’829 Patent col.11 1.7–col.12 1.2 (footnotes  
 4 added). Similar to the claim in *Monsanto*, the composition in claim 13 can be created only after  
 5 the composition in claims 10 and 11 are created; the composition of claim 13 *depends* on the  
 6 prior creation of the compositions recited in claims 10 and 11. Accordingly, claim 13 is a  
 7 dependent claim that depends from claim 11, which depends from claim 10.

8 Claim 14 recites: “The pharmaceutical composition for preparing medicaments for  
 9 therapeutic use in the treatment of human beings<sup>8</sup> as defined in claim 10 wherein said  
 10 composition is produced as a result of separation by differential solubility in a polar solvent of a  
 11 (6S) diastereoisomer from an initial mixture containing equal amounts of (6S) and (6R)  
 12 diastereoisomers.” ’829 Patent col.12 ll.3–8 (footnote added). Again, this composition can only  
 13 be created after the composition covered by claim 10 is first created. Therefore, claim 14 is also  
 14 a dependent claim that depends from claim 10.

15 In addition, the prosecution history further supports the Court’s conclusion that claims 13  
 16 and 14 are dependent claims. In fact, the application expressly provides for fourteen total claims  
 17 of which *only three* are independent claims. (Keane Decl. Ex. 12, at 7, ECF No. 54-12.)  
 18 Neither party disputes that these three independent claims consist of claim 1, claim 5, and claim  
 19 10. According to the patent application, the remaining eleven claims were claims that depended  
 20 from one of these three independent claims. Thus, the prosecution history also persuades the  
 21 Court, as Defendant urges, that claims 13 and 14 are dependent claims.

22  
 23  
 24 <sup>7</sup> The originally issued claim 13 refers to claim 12. However, the ’829 Patent includes a Certificate of Correction,  
 25 dated May 6, 2003, that recognizes that claim 13 should, in fact, refer to claim 11, rather than claim 12.

<sup>8</sup> The originally issued claim 14 recited “The pharmaceutical composition for therapeutic use for the treatment of  
 human beings . . .” ’829 Patent col.12 1.3-4. However, the ’829 Patent includes a third Certificate of correction,  
 dated January 22, 2013, which provides that claim 14 should recite “The pharmaceutical composition for  
 preparing medicaments for therapeutic use in the treatment of human beings . . .”

## 2. *Validity of claims 13 and 14*

“A patent shall be presumed valid.” 35 U.S.C. § 282(a). “To overcome this presumption of invalidity, the party challenging a patent must prove facts supporting a determination of invalidity by clear and convincing evidence.” *Schumer v. Lab Computer Sys., Inc.*, 308 F.3d 1304, 1315 (Fed. Cir. 2002); *see also* 35 U.S.C. § 282(a) (“The burden of establishing invalidity of a patent or any claim thereof shall rest on the party asserting such invalidity.”).

Defendant asserts that, not only are claims 13 and 14 dependent claims, but also that these claims are invalid because they *improperly* depend from claims 10 and 11. (See generally Resp. 19:26–22:21, ECF No. 53.) Specifically, Defendant contends that claims 13 and 14 are invalid because the dependent claims and the independent claims from which they depend relate to “non-overlapping subject matter.” (Resp. 20:15–17.)

Although this topic is infrequently litigated, the Federal Circuit's decision in *Pfizer, Inc. v. Ranbaxy Laboratories* appears to govern this issue. 457 F.3d 1284, 1291 (Fed. Cir. 2006). In *Pfizer*, the disputed dependent claim read: "The hemicalcium salt of the compound of claim 2." *Id.* However, claim 2, from which the disputed claim depended, claimed only atorvastatin acid and did "not include the pharmaceutically acceptable salts of atorvastatin acid."<sup>9</sup> *Id.*

Here, claim 13 suffers from a similar defect. One claim covers a composition that can be used to prepare a medicament and the other claims the actual medicament. Specifically, Claim 11, from which claim 13 depends, claims a composition *for preparing* a medicament. '829 Patent col.10 ll.63–65 (“The pharmaceutical composition *for preparing medicaments* for therapeutic use in the treatment of human beings . . .” (emphasis added)). In contrast, claim 13 does not recite a composition that can be used to prepare a medicament. *See* '829 Patent col.11

<sup>9</sup> The Court noted that, “[t]heoretically, a claimed acid could be liberally construed to include the corresponding salts. But here, given the absence of the ‘pharmaceutically acceptable salts thereof’ language which was used in claim 1, the intrinsic evidence would not have supported such an interpretation of claim 2.” *Pfizer*, 457 F.3d at 1291 n.6.

11.7–8. Rather, claim 13 claims the medicament itself that can be used for the actual treatment  
 2 of human beings. '829 Patent col.11 ll.7–8 (“[A] pharmaceutical composition for therapeutic use  
 3 for the treatment of human beings . . .”) The distinctions between the language of these two  
 4 claims is fatal to claim 13. As in *Pfizer*, these two claims “deal with non-overlapping subject  
 5 matter” and claim 13 must be invalid.

6 Because of the January 22, 2013 Certificate of Correction, claim 14 does not suffer from  
 7 this defect. This Certificate of Correction expressly alters the language of claim 14 to recite:  
 8 “The pharmaceutical composition *for preparing* medicaments for therapeutic use in the  
 9 treatment of human beings . . .” Thus, the subject matter of dependent claim 14 overlaps with  
 10 claim 10, from which claim 14 depends, because claim 10 also recites “[a] pharmaceutical  
 11 composition for preparing medicaments . . .” '829 Patent col.10 ll.47–48. Accordingly, the  
 12 Court concludes that Defendant has failed to carry its burden of establishing, by clear and  
 13 convincing evidence, that claim 14 is invalid.

14 **3. *The Court’s Construction***

15 For the reasons discussed above, the Court concludes that both claim 13 and claim 14 are  
 16 drafted in dependent format. Claim 13 depends from claim 11, which in turn depends from  
 17 claim 10. Claim 14 depends from claim 10.

18 In addition, the Court holds that claim 13 is invalid. However, Defendant failed to carry  
 19 its burden of establishing the invalidity of claim 14 by clear and convincing evidence; therefore,  
 20 the Court cannot conclude that claim 14 is invalid.

21 **VI. CONCLUSION**

22 **IT IS HEREBY ORDERED** that the proposed construction of the nine (9) terms  
 23 submitted by the parties are construed as contained within this Order. The Court construes the  
 24 primary nine (9) disputed claim terms in U.S. Patent No. 6,500,829 as follows:

25 // /

1	“mixture”	Plain and ordinary meaning
2	the “percentage” claim terms	Plain and ordinary meaning
3	“the balance of said composition consisting of the (6R) diastereoisomer”	the remaining amount of the mixture of (6S) and (6R) diastereoisomers is the (6R) diastereoisomers, and any impurities normally associated with the mixture of (6S) and (6R) diastereoisomers
4	“pharmaceutical composition for therapeutic use”	a pharmaceutical composition suitable for treating medical conditions
5	“pharmaceutical composition for preparing medicaments for therapeutic use for the treatment of human beings”	a pharmaceutical composition from which can be prepared a medicine suitable for treating medical conditions in human beings
6	“consists essentially of”	“the specified materials and those that do not materially affect the basic and novel characteristic(s) of the composition”
7	the “multiple dose” or “4,000 mg (4 grams)” claim terms	Plain and ordinary meaning; the pharmaceutical composition must contain enough of the (6S)/(6R) mixture to provide two or more doses of, at minimum, 2000 mg per dose of the mixture
8		
9		
10		
11		
12		

13 **IT IS FURTHER ORDERED** that claims 13 and 14 are both dependent claims. Claim  
 14 depends from claim 11. Claim 14 depends from claim 10.

15 **IT IS FURTHER ORDERED** that claim 13 is invalid as improperly dependent from  
 16 claim 11.

17 **IT IS FURTHER ORDERED** that this case shall be referred to Magistrate Judge Nancy  
 18 J. Koppe for the setting of the Post-Claim Construction Order Settlement Conference pursuant  
 19 to Local Rule 16.1-19(b).

20 **DATED** this 8th day of January, 2014.

21 **NUNC PRO TUNC DATE: December 31, 2013.**

22  
 23  
 24  
 25

Gloria M. Navarro  
 United States District Judge